Provided by Tiger Fintech (Singapore) Pte. Ltd.

Foghorn Therapeutics Inc.

4.03
+0.13003.33%
Volume:39.97K
Turnover:157.33K
Market Cap:224.12M
PE:-2.55
High:4.20
Open:3.98
Low:3.80
Close:3.90
Loading ...

Foghorn Therapeutics initiated with a Buy at B. Riley

TIPRANKS
·
30 Jan

Optimistic Outlook on Foghorn Therapeutics Amid Market Opportunities and Strategic Developments

TIPRANKS
·
30 Jan

BRIEF-Foghorn Therapeutics Inc. Files For Mixed Shelf Of Up To $300 Million - SEC Filing

Reuters
·
25 Jan

Foghorn Therapeutics Files $300 Million Mixed Securities Shelf

MT Newswires Live
·
25 Jan

Foghorn Therapeutics files $300M mixed securities shelf

TIPRANKS
·
25 Jan

Foghorn Therapeutics Outlines Year Ahead for Oncology Drug Candidates

MT Newswires Live
·
13 Jan

Foghorn Therapeutics Inc.: Strong Balance Sheet With Cash, Cash Equivalents, and Marketable Securities of $243.8 Mln Provides Cash Runway Into 2027

THOMSON REUTERS
·
13 Jan

Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025

THOMSON REUTERS
·
13 Jan

Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should Know

Zacks
·
10 Jan

More Unpleasant Surprises Could Be In Store For Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares After Tumbling 41%

Simply Wall St.
·
01 Jan

Foghorn Therapeutics Board Member Resignation Announced

TIPRANKS
·
30 Dec 2024

Foghorn Therapeutics price target lowered to $13 from $20 at H.C. Wainwright

TipRanks
·
18 Dec 2024

Foghorn Therapeutics price target lowered to $4 from $9 at Morgan Stanley

TIPRANKS
·
18 Dec 2024

Foghorn Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $13 From $20

THOMSON REUTERS
·
17 Dec 2024

Foghorn Therapeutics: Hold Rating Amid Strategic Pivot and Uncertainty in Drug Development

TIPRANKS
·
17 Dec 2024

Foghorn Therapeutics Shares Down 10.9% After Co Halts Independent Development of Cancer Treatment

THOMSON REUTERS
·
16 Dec 2024

Sector Update: Health Care Stocks Mixed Pre-Bell Monday

MT Newswires Live
·
16 Dec 2024

Foghorn Therapeutics Inc. : Jefferies Cuts Target Price to $14 From $18

THOMSON REUTERS
·
16 Dec 2024

Foghorn Therapeutics price target lowered to $14 from $18 at Jefferies

TIPRANKS
·
16 Dec 2024

Foghorn Therapeutics Discontinues Development of FHD-286 Clinical Program; Shares Fall Pre-Bell

MT Newswires Live
·
16 Dec 2024